BioSpace News Archive

- Data showed approximately 1 in 3 people diagnosed with migraine take a recommended acute prescription medication for a migraine attack, while less than 1 in 5 who suffer frequent migraine attacks take a recommended preventive prescription medication - OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) aims to further understand the burden, stigma and barriers faced by people living with migraine

NantHealth Announces Eviti Product Updates to Aid Efficiency and Reporting for Payers & NaviNet Product Updates to Enhance the User Experience

Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa Labs”) today announced that the underwriters for its previously announced public offering of common stock have fully exercised their option to purchase 90,000 additional shares of Mesa Labs common stock.

With a focus on screening local healthcare workers and first responders, the epidemiological study seeks to understand the prevalence of coronavirus infections in the community.

At this year’s cancer congress in Chicago (ASCO), novel hormone treatments of patients suffering from non-metastatic castration-resistant prostate cancer were recognized. There are currently no efficient treatment options for the condition. Prostate cancer is the most common form of cancer in the western world.

Case Medical today announced that it was awarded U.S. patent number 10,699,513 B2, by the U.S. Patent and Trademark office for “compositions and methods for handling potential prion contamination.”

The CDC Foundation and the Satcher Health Leadership Institute (SHLI) at Morehouse School of Medicine today announced a partnership to address the health equity implications of the COVID-19 pandemic. Support for this program is provided by the CDC Foundation’s COVID-19 emergency response fund.

To help ensure a safe and healthy workplace, GeneIQ’s molecular diagnostic laboratory is partnering with Dallas Children’s Advocacy Center (DCAC) as part of the agency’s new protocols for managing the coronavirus pandemic.

Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, announces the election of new independent directors, Alison Moore, Ph.D. and Stephen Dilly, MBBS, Ph.D. at the company’s 2020 Annual Meeting of Stockholders held earlier today.

Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its initial public offering of 12,105,263 shares of its common stock at an initial public offering price of $19.00 per share,